Preferred Name |
brivaracetam |
|
Synonyms |
1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)- UCB 34714 Briviact 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide UCB-34714 UCB34714 |
|
ID |
http://purl.bioontology.org/ontology/MESH/C482793 |
|
altLabel |
1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)- UCB 34714 Briviact 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide UCB-34714 UCB34714 |
|
cui |
C4083381 C1436082 C1699861 |
|
HM |
D011760 |
|
Inverse of RB |
U863JGG2IA 0 |
|
isa | ||
LT |
TRD |
|
Mapped to | ||
MDA |
20040319 |
|
MeSH Frequency |
237 |
|
MMR |
20161027 |
|
notation |
C482793 |
|
PA |
D000927 |
|
prefLabel |
brivaracetam |
|
SC |
1 |
|
Scope Statement |
A pyrrolidinone compound that is used to treat partial onset seizures in adult patients; structure in first source. |
|
SRC |
J Med Chem 2004 Jan 29;47(3):530-49 |
|
TERMUI |
T578120 T000908840 T000908444 T578123 T578121 T671415 T578122 T000908842 |
|
TH |
NLM (2004) FDA SRS (2017) USAN (19XX) INN (19XX) NLM (2006) NLM (2017) |
|
tui |
T109 T121 |